Indivior has announced new data from the two-year phase III analysis of the 24-month real-world observational study, RECOVER in individuals with moderate to severe opioid use disorder (OUD) following their transition from two Phase III clinical trials of Sublocade (buprenorphine extended-release) injection, for subcutaneous use (CIII) into a real-world setting. This is the first analysis to examine patient outcomes two years after receiving up to 18 months of treatment with Sublocade. The main findings from this analysis shows that of the 533 participants enrolled in RECOVER, 396 (74%) completed the 24-month assessment.
In addition, 218 participants (44%) self-reported sustained illicit opioid-free weeks for the entire 24-month period. Nearly half of the participants were employed over the assessment period; percentages increased from 35% at pre-trial screening to 45-48% at 24-months. As it relates to healthcare resource utilization over the entire 24-month period, 15% of participants reported staying overnight in a hospital and 12% reported having an emergency department visit.
Among the 495 participants who contributed data over the 24-month period, 69% of the cohort received substance use disorder treatment, of which buprenorphine medication assisted treatment was the most prevalent. These results were reported at the 82nd Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) held virtually from June 22-24, 2020.